Penicillin G concentrations required for prophylaxis against Group A Streptococcus infection evaluated using a hollow

Jessica R Tait1, Timothy C Barnett2, Kate E Rogers1

  • 1Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.

Abstract

Insights

New penicillin formulations aim to prevent acute rheumatic fever (ARF) and rheumatic heart disease (RHD). Penicillin G concentrations of at least 0.016 mg/L are needed to suppress Group A Streptococcus growth effectively.

Area of Science:

  • Microbiology
  • Pharmacology
  • Infectious Diseases

Background:

  • Acute rheumatic fever (ARF) and rheumatic heart disease (RHD) stem from Group A Streptococcus (Strep A) infections.
  • New long-acting penicillin formulations are being developed for ARF and RHD secondary prophylaxis.

Purpose of the Study:

  • To determine the necessary penicillin G concentrations for inhibiting Strep A growth.
  • To inform the development of novel penicillin formulations for ARF and RHD prevention.

Main Methods:

  • Minimum Inhibitory Concentration (MIC) and Minimum Bactericidal Concentration (MBC) assays for Strep A strains.
  • Hollow fiber model simulating in vivo conditions with varying penicillin G concentrations.
  • Mathematical modeling to analyze bacterial growth and eradication dynamics.

Main Results:

  • MIC and MBC for all tested Strep A strains were 0.008 mg/L.
  • Penicillin G concentrations ≥0.016 mg/L eradicated Strep A (M75611024, M1T15448) within 6 hours.
  • Lower concentrations (≥0.008 mg/L) eradicated Strep A (M18MGAS8232) within 24 hours.

Conclusions:

  • The study provides crucial data on penicillin G target concentrations for new ARF/RHD prophylactic agents.
  • Findings guide the development of effective long-acting penicillin formulations.
  • This research aids in combating ARF and RHD, particularly in vulnerable populations.

Related Concept Videos